Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy
{{output}}
Background: Current therapies for light chain (AL) amyloidosis target the plasma cell dyscrasia, but their effect on myocardial amyloid fibril burden remains poorly defined. ... ...
